What the disparagement cases tell us about abuses by object (and the forthcoming Guidelines)

I have spent the past few weeks (re-)reading in detail the case law and administrative practice on disparagement and related issues, including landmark rulings such as (the other) Hoffmann-La Roche and AstraZeneca. The Commission decision in Teva-Copaxone is a fascinating read that builds on the extensive experience acquired at the national level (see here for [ ]